LivaNova Reports Q3 2025 Earnings with Strong Revenue Growth
LivaNova reported Q3 2025 earnings with total revenue of $358 million, a 13% increase in organic revenue growth, and a 16% rise in cardiopulmonary segment revenue. The company raised its cardiopulmonary revenue guidance for the year due to strong performance in Heart-Lung Machine sales and consumables.
Tickers: $LIVN
Topics: cardiopulmonary epilepsy Essenz organic_growth revenue